Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?

被引：1

作者：

Brown, Jennifer R. ^{[2
]}

Wierda, William G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

[2] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 11期

关键词：

RITUXIMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; CLL;

D O I：

10.6004/jnccn.2019.5026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the enormous progress made in treatment and management, many oncologists have called this the golden age of chronic lymphocytic leukemia (CLL). The past few years alone have seen the approval of multiple agents, including small molecule inhibitors that have led to longer, more durable periods of disease control. However, the introduction of these new drugs into the armamentarium has raised an important question regarding standard of care: is there still a role for chemoimmunotherapy in the first-line setting? At the NCCN 2019 Annual Congress: Hematologic Malignancies, Drs. William G. Wierda and Jennifer R. Brown presented opposing sides of the debate.

引用

页码：1408 / 1410

页数：3

共 10 条

[1] Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p [J].

Barnes, James, I ;

Divi, Vasu ;

Begaye, Adrian ;

Wong, Russell ;

Coutre, Steven ;

Owens, Douglas K. ;

Goldhaber-Fiebert, Jeremy D. .

BLOOD ADVANCES, 2018, 2 (15) :1946-1956

[2] Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 [J].

Barr, Paul M. ;

Robak, Tadeusz ;

Owen, Carolyn ;

Tedeschi, Alessandra ;

Bairey, Osnat ;

Bartlett, Nancy L. ;

Burger, Jan A. ;

Hillmen, Peter ;

Coutre, Steven ;

Devereux, Stephen ;

Grosicki, Sebastian ;

McCarthy, Helen ;

Li, Jianyong ;

Simpson, David ;

Offner, Fritz ;

Moreno, Carol ;

Zhou, Cathy ;

Styles, Lori ;

James, Danelle ;

Kipps, Thomas J. ;

Ghia, Paolo .

HAEMATOLOGICA, 2018, 103 (09) :1502-1510

[3] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial [J].

Eichhorst, Barbara ;

Fink, Anna-Maria ;

Bahlo, Jasmin ;

Busch, Raymonde ;

Kovacs, Gabor ;

Maurer, Christian ;

Lange, Elisabeth ;

Koeppler, Hubert ;

Kiehl, Michael ;

Soekler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Koechling, Georg ;

Ploeger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Trneny, Marek ;

Fischer, Kirsten ;

Doehner, Harmut ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Boettcher, Sebastian ;

Hallek, Michael .

LANCET ONCOLOGY, 2016, 17 (07) :928-942

[4] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions [J].

Fischer, K. ;

Al-Sawaf, O. ;

Bahlo, J. ;

Fink, A. -M. ;

Tandon, M. ;

Dixon, M. ;

Robrecht, S. ;

Warburton, S. ;

Humphrey, K. ;

Samoylova, O. ;

Liberati, A. M. ;

Pinilla-Ibarz, J. ;

Opat, S. ;

Sivcheva, L. ;

Du, K. Le ;

Fogliatto, L. M. ;

Niemann, C. U. ;

Weinkove, R. ;

Robinson, S. ;

Kipps, T. J. ;

Boettcher, S. ;

Tausch, E. ;

Humerickhouse, R. ;

Eichhorst, B. ;

Wendtner, C. -M. ;

Langerak, A. W. ;

Kreuzer, K. -A. ;

Ritgen, M. ;

Goede, V. ;

Stilgenbauer, S. ;

Mobasher, M. ;

Hallek, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) :2225-2236

[5] Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial [J].

Fischer, Kirsten ;

Bahlo, Jasmin ;

Fink, Anna Maria ;

Goede, Valentin ;

Herling, Carmen Diana ;

Cramer, Paula ;

Langerbeins, Petra ;

von Tresckow, Julia ;

Engelke, Anja ;

Maurer, Christian ;

Kovacs, Gabor ;

Herling, Marco ;

Tausch, Eugen ;

Kreuzer, Karl-Anton ;

Eichhorst, Barbara ;

Boettcher, Sebastian ;

Seymour, John F. ;

Ghia, Paolo ;

Marlton, Paula ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Doehner, Hartmut ;

Stilgenbauer, Stephan ;

Hallek, Michael .

BLOOD, 2016, 127 (02) :208-215

[6] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE [J].

Moreno, Carol ;

Greil, Richard ;

Demirkan, Fatih ;

Tedeschi, Alessandra ;

Anz, Bertrand ;

Larratt, Loree ;

Simkovic, Martin ;

Samoilova, Olga ;

Novak, Jan ;

Ben-Yehuda, Dina ;

Strugov, Vladimir ;

Gill, Devinder ;

Gribben, John G. ;

Hsu, Emily ;

Zhou, Cathy ;

Clow, Fong ;

James, Danelle F. ;

Styles, Lori ;

Flinn, Ian W. .

BLOOD, 2018, 132

[7] Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia [J].

Shanafelt, T. D. ;

Wang, X. V. ;

Kay, N. E. ;

Hanson, C. A. ;

O'Brien, S. ;

Barrientos, J. ;

Jelinek, D. F. ;

Braggio, E. ;

Leis, J. F. ;

Zhang, C. C. ;

Coutre, S. E. ;

Barr, P. M. ;

Cashen, A. F. ;

Mato, A. R. ;

Singh, A. K. ;

Mullane, M. P. ;

Little, R. F. ;

Erba, H. ;

Stone, R. M. ;

Litzow, M. ;

Tallman, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (05) :432-443

[8] A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRM Cancer Research Group (E1912) [J].

Shanafelt, Tait D. ;

Wang, Victoria ;

Kay, Neil E. ;

Hanson, Curtis A. ;

O'Brien, Susan M. ;

Barrientos, Jacqueline C. ;

Erba, Harry P. ;

Stone, Richard M. ;

Litzow, Mark R. ;

Tallman, Martin S. .

BLOOD, 2018, 132

[9] Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia [J].

Thompson, Philip A. ;

Tam, Constantine S. ;

O'Brien, Susan M. ;

Wierda, William G. ;

Stingo, Francesco ;

Plunkett, William ;

Smith, Susan C. ;

Kantarjian, Hagop M. ;

Freireich, Emil J. ;

Keating, Michael J. .

BLOOD, 2016, 127 (03) :303-309

[10] Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL [J].

Woyach, J. A. ;

Ruppert, A. S. ;

Heerema, N. A. ;

Zhao, W. ;

Booth, A. M. ;

Ding, W. ;

Bartlett, N. L. ;

Brander, D. M. ;

Barr, P. M. ;

Rogers, K. A. ;

Parikh, S. A. ;

Coutre, S. ;

Hurria, A. ;

Brown, J. R. ;

Lozanski, G. ;

Blachly, J. S. ;

Ozer, H. G. ;

Major-Elechi, B. ;

Fruth, B. ;

Nattam, S. ;

Larson, R. A. ;

Erba, H. ;

Litzow, M. ;

Owen, C. ;

Kuzma, C. ;

Abramson, J. S. ;

Little, R. F. ;

Smith, S. E. ;

Stone, R. M. ;

Mandrekar, S. J. ;

Byrd, J. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) :2517-2528

← 1 →